Overexpression of fatty acid synthase in middle eastern epithelial ovarian carcinoma activates AKT and its inhibition potentiates cisplatin-induced apoptosis

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 635-645

  Uddin, Shahab ^a   Jehan, Zeenath ^a   Ahmed, Maqbool ^a   Alyan, Aisha ^a   Al Dayel, Fouad ^a   Hussain, Azhar ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C 75; CASPASE; CISPLATIN; FATTY ACID SYNTHASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE EAST; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

4-BUTYROLACTONE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; DRUG SYNERGISM; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MIDDLE AGED; MIDDLE EAST; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 79960746924     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00046     Document Type: Article

References (35)

1. Cannistra SA. (2004) Cancer of the ovary. N. Eng. J. Med. 351:2519-29.
2. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. (2008) Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J. Clin. Endocrinol. Metab. 93:1592-9.
3. Asturias FJ, et al. (2005) Structure and molecular organization of mammalian fatty acid synthase. Nat. Struct. Mol. Biol. 12:225-32.
4. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in-situ breast carcinoma. Clin. Cancer Res. 3:2115-20.
5. Uddin S, et al. (2008) Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab. 93:4088-97.
6. Rashid A, et al. (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am. J. Pathol. 150:201-8.
7. Sehdev AS, Kurman RJ, Kuhn E, Shih IeM. (2010) Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod. Pathol. 23:844-55.
8. Cerne D, Zitnik I P, and Sok M. (2010) Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. Arch. Med. Res. 41:405-9.
9. Pizer ES, et al. (2001) Increased fatty acid synthase as a therapeutic target in androgenindependent prostate cancer progression. Prostate. 47:102-10.
10. Kuhajda FP. (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 16:202-8.
11. Kuhajda FP. (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66:5977-80.
12. Ueda SM, et al. (2010) Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J. Oncol. 28:5191.
13. Pizer ES, et al. (2001) Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 47:102-10.
14. Pizer ES, et al. (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 60:213-8.
15. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63:3799-804.
16. Pizer ES, et al. (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56:1189-93.
17. Bandyopadhyay S, et al. (2005) FASN expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FASN siRNA to induce apoptosis. Oncogene. 24:5389-95.
18. Porstmann T, et al. (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene. 24:6465-81.
19. Wang HQ, et al. (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 24:3574-3582.
20. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. (2003) PI3K/Akt and apoptosis: size matters. Oncogene. 22:8983-98.
21. Nicholson KM, Anderson NG. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381-95.
22. Häusler P, et al. (1998) Protection of CD95- mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur. J. Immunol. 1:57-69.
23. Di Cristofano A, et al. (1999) Impaired FASN response and autoimmunity in Pten+/- mice. Science. 285:21.
24. Bavi P, et al. (2010) Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic K-RAs alterations. Mol. Cancer. 9:203.
25. Russel P. (1994). Surface epithelial-stromal tumors of the ovary. 4th edition. In: Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed.) Springer- Verlag, New York, pp. 705-82.
26. Uddin S, et al. (2006) Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 108:4178-86.
27. Camp RL, Dolled-Filhart M, Rimm DL. (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome based cut-point optimization. Clin. Cancer Res. 10:7252-9.
28. Hussain AR, et al. (2007) Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res. 67:3888-97.
29. Uddin S, et al. (2009) High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am. J. Gastroenterol. 104:1790-801.
30. Ciechomska I, Pyrzynska B, Kazmierczak P, Kaminska B. (2003) Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene. 22:7617-27.
31. Cohen P, Alessi DR, Cross DA. (1997) PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 410:3-10.
32. Dan HC, et al. (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 279:5405-12.
33. Gastman BR. (2001) Apoptosis and its clinical impact. Head Neck. 23:409-25.
34. Duriez PJ, et al. (1997) Characterization of antipeptide antibodies directed towards the automodification domain and apoptotic fragment of poly (ADP-ribose) polymerase. Biochim. Biophys. Acta. 1334:65-72.
35. Piccart MJ, Lamb H, Vermorken JB. (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol. 12:1195-203.